PME signs Research Collaboration Agreement with UCSF
Stock | Pro Medicus Ltd (PME.ASX) |
---|---|
Release Time | 15 Apr 2025, 10:31 a.m. |
Price Sensitive | Yes |
Pro Medicus signs research collaboration with UCSF
- Multi-year research collaboration agreement with UCSF
- UCSF to leverage Visage AI Accelerator platform
- Collaboration to facilitate AI research and development
Pro Medicus Limited, a leading healthcare informatics company, has announced that its wholly owned U.S. subsidiary, Visage Imaging, Inc., has signed a multi-year research collaboration agreement with the University of California, San Francisco (UCSF). The agreement will serve as the framework for collaboration between the two parties to facilitate development and commercialisation leveraging the Visage AI Accelerator platform. The Visage AI Accelerator program was designed to closely align Visage's engineering and product development capability with clinical research partners like UCSF, who have a depth of clinical knowledge and extensive research expertise. The collaboration will provide a unique set of tools for data de-identification, collection, curation, analysis and 'path-to-production' in research projects, bringing the efficiency and speed of Visage technology to research and resulting in a unified link between the two domains. Pro Medicus sees AI playing a significant role in healthcare, particularly in the field of imaging IT, and has optimized its Visage 7 platform for AI, enabling both its own and third-party algorithms to be seamlessly integrated into the clinician's desktop. The research collaboration agreement with UCSF is seen as another significant piece of Pro Medicus' AI strategy, with the potential to develop innovative AI solutions that meet well-defined clinical goals and ultimately lead to better patient outcomes.
Pro Medicus sees AI playing a significant role in healthcare, particularly in the field of imaging IT, and this research collaboration agreement with UCSF has the potential to develop innovative AI solutions that meet well-defined clinical goals and ultimately lead to better patient outcomes.